CENTRAL MEDICAL SERVICES SOCIETY

Ministry of Health & Family Welfare (Autonomous Body under MoHFW, Govt. of India) 2nd Floor, Vishwa Yuvak Kendra, Pandit Uma Shankar Dikshit Road, Chanakyapuri, New Delhi-110021 PHONE -:011-21410905/6, Fax -:011-21410849

Date: - 22/07/2024

Minutes of Pre-bid Meeting For Procurement of Tenofovir 300mg+ Lamivudine 300mg+ Dolutegravir 50mg (TLD) for NACO (Online Risk Purchase Tender) CPP Tender ID.: 2024_CMSS_815568_1, Dated 09/07/2024 Pre-bid Meeting held on 12/07/2024 at 11:00 AM

- 1. Following officials were present during the Pre-bid meeting: -
 - (i) Dr. Bhawani Singh, Deputy Director (NACO)
 - (ii) Mr. Pramod B Somnathe, GM (Procurement), CMSS
 - (iii) Mr. Lava Mishra, AGM (Procurement), CMSS
 - (iv) Ms. Neetu, Manager (Procurement), CMSS
- 2. Following representative from prospective bidder was present during the Pre-bid meeting: -

| Sr. No. | Name of Representative | Name of Bidder |
|---------|--------------------------------|----------------------------------|
| 1. | Ms. Bhavya Devi | M/s Strides |
| 2. | Mr. Manoj Singh Rathore | M/s Aurobindo Pharma Ltd |
| 3. | Ms. Poonam Koli | M/s Bharat Parenterals Pvt Ltd |
| 4. | Mr. Gaurav Sharma | M/s Emcure Pharma |
| 5. | Ms. Rohini Karde- On VC | M/s Macleods Pharmaceuticals Ltd |
| 6. | Mr. Bala Kishore Sharma- On VC | M/s Maylan Pharmaceuticals Ltd |
| 7. | Mr. Pawan Thakran | M/s Lupin Ltd |

3. Queries from following prospective bidders were received via email: -

| Sr. No. | Name of the bidders | | | | | |
|---------|--|--|--|--|--|--|
| 1. | M/s Aurobindo Pharma Ltd | | | | | |
| 2. | M/s AnshGenex Industry Inc. | | | | | |
| 3. | M/s Centurion Laboratories Pvt Ltd | | | | | |
| 4. | M/s Macleods Pharmaceuticals Ltd | | | | | |
| 5. | M/s Mylan Laboratories Ltd | | | | | |
| 6. | M/s Lupin Ltd | | | | | |
| 7. | M/s Hetero Labs Ltd | | | | | |
| 8. | M/s Pivotal Bio Research Pvt Ltd (OPC) | | | | | |
| 9. | M/s J Duncan Healthcare Pvt Ltd | | | | | |
| 10. | M/s Bharat Parenterals Ltd | | | | | |

4. Points raised by representative of prospective bidder was discussed. After due consideration of the queries, the Response/Amendments are enclosed.

ANNEXURE-1

| Pre-bid queries raised | ov the | prospective bidde | er & Response | Amendments by CMSS |
|------------------------|--------|-------------------|---------------|--------------------|
| 1 | 2 | 1 1 | 1 / | 2 |

| Sr. | As per tender Description | Tender | Bidder's Query | Response/ Amendments |
|-----|--|--|---|--|
| No. | | Clause No. & Page No. | 2 | |
| 1. | Technical Specification 4 (g) Tenderer should quote for 100% of the tender quantity of | Annexu re-1A & Pg No. 36 to 47 4 (g), Annexu | There is no technical specification for Tenofovir 300mg + Lamivudine 300mg + Dolutegravir 50 mg (TLD) at pg no 36 to 47. Kindly confirm technical specification. Kindly clarifies the methodology of placing | Clarified as: Technical specification is at Pg No. 36 to 47 of tender document. Kindly go through the same. Clarified as: |
| | each items quoted and the tenderer shall have an annual production capacity not less than one and half times the quantity quoted for each schedule. Annexure-I- 100% qty to L1 bidder 10.3 In exercising of the powers conferred in Section 11 of the Micro, Small and Medium Enterprises Development (MSMED) Act 2006, the Government has notified a new Public Procurement Policy for Micro & Small Enterprises effective from 9th November 2018. 13.4 CMSS will counter offer the lowest rate (L1 rate) to other Tenderers in the order of their ranking i.e. L2, L3 and so on will be asked to match the L1 price. 13.5 (i). In order to maintain uninterrupted supplies, the CMSS will place orders with minimum of two suppliers for tendered product with 70% of the orders given to L1 and the balance 30% to the next | re-I, 10.3, 13.4, 13.5 (i) & Pg No. 7, 35, 19, 22 | orders and MSE should get the 25% order as per MSMED act and L2/L3 will be asked to match L1 to get 30% order as per Clause no. 13.5(i). So kindly amend accordingly. Please clarify whether the entire quantity will be placed with One supplier or the quantity will be split among two or more suppliers. We request you to also consider providing the option to quote for 50% of the tender quantity. Refer to this clause we hereby request you to kindly re-confirm that the order will split in 70:30 ratio or 100%. | 100% quantity will be awarded to L1 bidder however tender clause no. 10.3 will also be followed in case L1 bidder is non-MSE bidder. |
| 3. | Matched Lowest Tenderer. Bank Guarantee (as per Annexure-XIV) can also be accepted as a mode of payment and the named beneficiary shall be Central Medical Services Society. The Bank guarantee shall be issued by a bank (Nationalized or Scheduled Bank) in India to make it | 9.1 (b) & Pg No. 16 | Format of Bank Guarantee for Earnest Money Deposit: As per Clause 9.1 (b) on Page 16 and Annexure III Format on Page 51 of tender document, format as per Annexure XIV is to be submitted as EMD. | Amended as: Bank Guarantee (as per Annexure-XIII) can also be accepted as a mode of payment and the named beneficiary shall be Central Medical Services Society. The Bank guarantee shall be issued by a bank |

| | the purchaser. The Bank Guarantee shall be in the format as per Annexure-XIV provided in the tender document. EMD shall remain valid for 45 days beyond the validity period for the bid and will be extended accordingly beyond any extension subsequently requested by purchaser. | 10.2 0 | However, the BG format for EMD is provided in Annexure XIII. You are therefore requested to issue a suitable amendment to avoid any confusion at a later date. | Bank) in India to make it enforceable and acceptable to the purchaser. The Bank Guarantee shall be in the format as per Annexure-XIII provided in the tender document. EMD shall remain valid for 45 days beyond the validity period for the bid and will be extended accordingly beyond any extension subsequently requested by purchaser. |
|----|--|------------------|--|---|
| 4. | If the supply reaches the designated consignee places or CMSS Warehouse after scheduled delivery date mentioned in LOA/P.O, liquidated damages will be levied @2.5% per week to be applied proportionately on per day basis up to a maximum of 10% of P.O. Cost, irrespective of the fact that whether the CMSS has suffered any damage/ loss or not, on account of delay in effecting supply. If the last scheduled delivery day happens to be a holiday the supply will be accepted on the next working day without any penalty. | 18.2 & Pg No. 30 | It is requested that penalty clause may please be revised to 0.5% per week as the current slab is too high. We request you to consider revising the liquidated damages to 0.5% per week to be applied proportionately on per day basis up to a maximum of 10% of P.O. We request you to please take LD as on minimum basis. Please reduce liquidated damages from 2.5% per week to 0.5% per week. If the supply reaches the designated consignee places or CMSS Warehouse after scheduled delivery date mentioned in LOA/P.O, liquidated damages will be levied @ 0.5% per week to be applied proportionately on per day basis up to a maximum of 10% of P.O. Cost, irrespective of the fact that whether the CMSS has suffered any damage/ loss or not, on account of delay in effecting supply. If the last scheduled delivery day happens to be a holiday the supply will be accepted on the next working day without any penalty. Reasons: - To compliance with DOE/GFR or CMSS existing tenders. 1. Refer to this clause, we hereby request you to kindly remove this clause or to reduce the percentage to 0.1 % penalty. | Clarified as: Kindly follow the tender terms & conditions. |

| 5. | Delivery Schedule: | Annexu | We request you to extend the | Clarified as: |
|----|--|-------------|--|--|
| | TDANCHE I 10 (0 (0 701 | re I | delivery schedule as follows: | Vie dly fallows the tan day tarms |
| | TRANCHEI-12,68,60,731tablets to be delivered within 90 | & Pg No. | Tranche I- 12,68,60,731 | Kindly follow the tender terms & conditions. |
| | days from the date of issue of | 35 | tablets to be delivered within | a conditions. |
| | LOA. TRANCHE II- | | 120 days from the date of | |
| | 12,68,60,970 tablets to be | | issue of LOA | |
| | delivered within 91-180 days | | | |
| | from the date of issue of LOA. | | Tranche II- 12,68,60,970 | |
| | TRANCHE III- 12,63,43,663 | | tablets to be delivered within | |
| | tablets to be delivered within | | 121-180 days from the date of | |
| | 181-330 days from the date of | | issue of LOA | |
| | issue of LOA. | | Tranche I- 12,63,43,663 | |
| | | | tablets to be delivered within | |
| | | | 181-330 days from the date of issue of LOA | |
| | | | Once we receive the award, | |
| | | | we have to start with | |
| | | | securing required API, | |
| | | | initiating API testing, | |
| | | | followed by API to FPP | |
| | | | conversion which involves | |
| | | | several processes like | |
| | | | granulation, compression, coating, packing, batch | |
| | | | release by QA/QC and | |
| | | | issuing COA. | |
| | | | 0 | |
| | | | These processes itself takes | |
| | | | minimum 60-90 days | |
| | | | depending upon the product, | |
| | | | manufacturing process & | |
| | | | required quantities by the customer. | |
| | | | customer. | |
| | | | Once we share the COA with | |
| | | | CMSS, we need to get the Pre | |
| | | | Dispatch Inspection | |
| | | | organized. And once the | |
| | | | inspection is performed, we | |
| | | | may have to wait for the | |
| | | | report before dispatching the goods by road to the CMSS | |
| | | | warehouses-total 18 | |
| | | | locations. | |
| | | | | |
| | | | There are total 18 locations | |
| | | | where we need to dispatch | |
| | | | the goods the transit lead | |
| | | | time is between approx. 5 days to 45 days including the | |
| | | | time required to secure | |
| | | | POD's etc. | |
| | | | | |
| | | | So considering all the above | |
| | | | activities, we hereby request you to amend the delivery | |
| | | | timeline as specified below: | |
| | | | 1 | |
| | | | TRANCHE I- 12,68,60,731 | |
| | | | tablets to be delivered within | |

| | | D | 120 days to 150 days from the date of issue of LOA. TRANCHE II- 12,68,60,970 tablets to be delivered within 151-180 days from the date of issue of LOA. TRANCHE III- 12,63,43,663 tablets to be delivered within 181-350 days from the date of issue of LOA. | Chaiffind an |
|----|---|---------------------|---|--|
| 6. | This tender is for procurement of Tenofovir 300mg+ Lamivudine 300mg+ Dolutegravir 50mg (TLD) for NACO at the risk & cost of the defaulter supplier against CMSS Purchase Order No. CMSS/PROC/2023- 24/NACO/021/059 & CMSS/PROC/2023- 24/NACO/021/060 dated 03/10/2023 awarded against tender no. CMSS/PROC/2023- 24/NACO/021 opened on 25/07/2023. | Page 5 | We request you to elaborate the eligibility criteria for participating in this tender in light of the indicated default in the tender opened on 25/07/2023. | Clarified as: Kindly follow the tender terms & conditions. |
| 7. | Tenderer should have supplied 20% of the quoted quantity of same or similar items during the last two financial years. Bidder should submit Purchase order copies and certificate duly issued by statutory auditor/Practicing Chartered Accountant of the company on his letter head by certifying the quantities manufactured and marketed in trade, export, open market, sold to government institutions, private bodies etc. and the marketed quantities are not less than at least 20% of the quoted/ similar items. Similar Items here relate to the following: - Similar item means quoted/any ARV Drug Supply/Sale/Service order under loan license arrangement shall not be considered. | 4 (h) & Pg No. 8 | We request you to elaborate the eligibility criteria for participating in this tender in light of the indicated default in the tender opened on 25/07/2023. We would like to draw you attention to the clause no. 4 (h) of Eligibility Criteria of Original tender No. CMSS/PROC/2023- 24/NACO/021, wherein it is stated that "Tenderer should quote at least for 50% of the tender quantity of each items quoted and the tenderer shall have an annual production capacity not less than one and half times the quantity quoted for each schedule". Furthermore, it is understood that as per the GFR under risk purchase, the Buyer/TIA has the right to procure the same material from alternative sources. As per the terms of original tender we request you to kindly consider our request and amend the said clause accordingly. | Clarified as: Kindly follow the tender terms & conditions. |

| | | | Sir, hope you will consider our request and allow us to quote for 50% of tender quantity and issue a suitable amendment in this regard. Relaxed the such conditions for MSME or Startup manufacturers in line with Deptt. Of Expenditure guidelines/ Orders/ Circulars. | |
|----|--|--|---|--|
| 8. | Annexure A & Annexure B | Annexu re XXII & Pg No. 82- 83 | Kindly clarify regarding this requirement. We have obtained the license from Medicines Patent Pool to supply TLD in India with due royalties to be paid as per the licensing agreement. Tab. Tenofovir 300 mg + Lamivudine 300 mg + Dolutegravir 50 mg is under patent and supplied under agreement from the patent holder. So, this product is to be procured from the approved medicine pool suppliers only. We request CMSS to consider only MPP-sublicensed manufacturers' participation in this tender (along with a supporting signed sub- license copy of the MPP-ViiV DTG license). We understand we have to submit any one of the Annexure form, kindly confirm. | Clarified as: Kindly follow the tender terms & conditions. |
| 9. | Tenderer should submit a certificate from the statutory auditor or cost auditor of the company (in the case of companies) or from a practicing cost accountant or practicing chartered accountant (in respect of suppliers other than companies) giving the percentage of local content at the time of submission of bid as per Annexure-XVII. | 6 (u) & Pg No. 13 | Request you to please allow the local content certificate from company Chartered Accountant (in case of companies) also. | Clarified as: Kindly follow the tender terms & conditions. |

| 10. | Tenderer should have supplied 20% of the quoted quantity of same or similar items during the last two financial years. Bidder should submit Purchase order copies and certificate duly issued by statutory auditor/Practicing Chartered Accountant of the | 6.2 (e & j) & Pg No. 11- 12 | As per the above two clauses, the two certificates are showing the same data i.e., last 2 years supplied / marketed quantities and the performance. Hence instead of taking two separate certificates from CA request you to kindly look in to this | Clarified as: Kindly follow the tender terms & conditions. |
|-----|--|--------------------------------------|---|--|
| | company on his letter head by certifying the quantities manufactured and marketed in trade, export, open market, sold to government institutions, private bodies etc. and the marketed quantities are not less than at least 20% of the quoted/ similar items. | | and make it as one Annexure from CA. | |
| | Performance Statement to establish 2 years market standing as per format given in Annexure-IV. | | | |
| 11. | (i). Long Term (Real Time) Stability Data of the quoted product in specified packing for at least for 3 batches, to support shelf life. However, For the drugs recently introduced drugs in the county (introduced in the last two years), the requirement for Long Term (Real Time) Stability Data of the quoted product in specified packing for at least for 3 batches, to support shelf life shall be waived off. Point no (iii) shall be applicable. (ii). Only for the drugs introduced in Indian Pharmacopoeia in the recent past (last 2yrs), Long Term (Real Time) Stability Data for previously approved Pharmacopoeia or In-house Standards shall be accepted, as the case may be. (iii). Accelerated Stability data for a period of 6 months in specified packing for at least 3 batches and available long term (Real Time) stability data as available for the quoted product shall be submitted. (iv). Certificate of Analysis of one batch of the quoted product should be submitted. | 6.2 (n) & Pg No. 12 | We request you to kindly accept the Stability data in In- House Standard and however the stocks shall be supplied with IP specification. | Clarified as: Kindly follow the tender terms & conditions. |

| 12. | Payments for supply will be | 17.4, | Please ensure that payments | Clarified as: |
|-----|---|----------|---|--------------------------------|
| | made only after completion of | 17.5 & | should be cleared within 60 | |
| | supply of Items ordered in the | Pg No. | days from the date of | Kindly follow the tender terms |
| | individual Purchase Order | 28 | submission of Invoices. | & conditions. |
| | PROVIDED quality reports are | | Currently payments are | |
| | acceptable. The CMSS shall | | invariably delayed by | |
| | endeavour to make payment | | Tender Authority. | |
| | within 75 days in respect of items requiring sterility tests | | In addition to the referred tender clause. | |
| | and | | tender clause. | |
| | within 60 days in respect of | | Payment should be release to | |
| | items requiring non- sterility | | MSME manufacturers | |
| | test from the date of submission | | according to MSME | |
| | of invoice or from the date of | | provisions by GoI. | |
| | receipt of material, whichever is | | | |
| | later along with all the relevant | | Delay in Payment: - CMSS | |
| | documents of tender. | | will have to pay penalty | |
| | | | equivalent to LD charges | |
| | | | clause (18.2) | |
| | | | Refer to clause we request to release the payment after the | |
| | | | supplies of Tranche wise | |
| | | | quantities instead of 50% | |
| | | | order quantity. | |
| | | | We request to remove this | |
| | | | certificate to submit along | |
| | | | with Post Shipment | |
| | | | documents. | |
| | | | | |
| | | | This is because, refer to past | |
| | | | supplied tender, we are | |
| | | | unable to get the CRC copy from each consignee & due to | |
| | | | which we are unable to | |
| | | | submit the bills and so our | |
| | | | payments are stucked. | |
| | | | | |
| | | | So allow us to submit the | |
| | | | POD's instead of CRC along | |
| | | | with Post Shipment | |
| 10 | T 1 1 1 1 4 6 4000/ | | documents. | |
| 13. | Tenderer should quote for 100% | 4 (g) & | We would like to request you | Clarified as: |
| | of the tender quantity of each items quoted and the tenderer | Pg No. 7 | to allow us to quote for 50% | Kindly follow the tender terms |
| | shall have an annual production | | of the tender quantity instead of 100% and place order for | & conditions. |
| | capacity not less than one and | | at least two bidders. This | |
| | half times the quantity quoted | | adjustment will facilitate | |
| | for each schedule. | | timely and reliable supply of | |
| | | | the product, thereby | |
| | | | ensuring the program is not | |
| | | | affected by delays or non- | |
| | | | supply. | |
| | | | Tenderer should quote for | |
| | | | minimum 50% of the tender | |
| | | | quantity of each items quoted and the tenderer shall | |
| | | | have an annual production | |
| | | | capacity not less than one | |
| | | | and half times the | |
| | | | quantity quoted for each | |
| | | | schedule. | |

| 14. | Technical Specification | Annexu re 1A & Pg No. 36 | Tenderer should quote for minimum 50% of the tender quantity of each items quoted and the tenderer shall have an annual production capacity not less than one and half times the quantity quoted for each schedule. Currently, we are supplying TLD stocks without outer cartons and request to accept the same for this tender. | Clarified as: Product can be provided without outer carton, patient information leaflet (PKI) to be placed on the top of the Bottle in the action of the Bottle in |
|-----|---|-----------------------------------|--|---|
| 15. | Technical Specification | Annexu re 1A & Pg No. 36 | As per the specification Tab. Tenofovir 300 mg + Lamivudine 300 mg + Dolutegravir 50mg is required in a pack of bottles containing 30 tabs. Please note that globally this product is supplied in a bottle of 90 tabs. It is requested that kindly consider packing 90 tabs in the bottle for this product. Request to allow us to supply Packs of 90's instead of 30's pack. | the ratio of 1:10 per bottle. Clarified as: Kindly follow the tender terms & conditions. |
| 16. | Bid Submission End Date and Time: 31.07.2024 till 03:00 PM | | We request CMSS to publish MOM as early as possible so that bidders can complete technical bid preparation in time. We required 10 days to get the documents. So, fix the number of days between MOM and the bid submission date at least 10 days. We request CMSS to extend the Tender submission closing date for at least 10 days to obtain the required documents from local FDA and other government of ices. Kindly extend the Bid Submission end date 07.08.2024 | Clarified as: Kindly follow the tender terms & conditions. |

| | | | TA7 1 1 1 | |
|-----|--|----------------------------------|--|---|
| | | | We hereby request to extend the Tender, as you have floated multiple tenders at | |
| | | | the same time | |
| 17. | Only Class-1 and Class-2 local supplier shall be eligible for | 4 (a) & Pg No. 6 | Class-1, Class-2 & Non local supplier shall be eligible for | Clarified as: |
| | participation. Bids from supplier (MSE/Non MSE) as defined in Department of Pharmaceuticals under Ministry of Chemicals and Fertilizers order no. F.No 31026/65/2020- MD dated 30.12.2020 shall be accepted. Bids from firms/vendors other than Class- 1 and Class-2 local supplier (MSE/Non MSE) shall be | 1,51,00.0 | participation. Bids from supplier (MSE/Non MSE) as defined in Department of Pharmaceuticals under Ministry of Chemicals and Fertilizers order no. F.No 31026/65/2020-MD dated 30.12.2020 shall be accepted. Remarks: - Tender Published against risk | Kindly follow the tender terms & conditions. |
| | summarily rejected. | | purchase w.r.o defaulting suppliers. | |
| 18. | The invitation to bid is open to domestic manufacturers (Indian Manufacturers) only. | 4 (b) & Pg No. 6 | The invitation to bid is open for Indian manufacturers and their authorized agents/distributors or Global suppliers and their agents. | Clarified as: Kindly follow the tender terms & conditions. |
| | | | NOTE: - As this Tender Published against risk purchase w.r.t. defaulting suppliers, means in the open market i.e., distributor/ Dealer permissible. The invitation to bid is open | |
| | | | to domestic manufacturers (Indian manufacturers)/or/ and their authorized agencies or Global manufacturers or their agents. | |
| | | | Remarks: - Tender Published against risk purchase w.r.t. defaulting suppliers. As per tender provisions 5.6 (c), 16.8 (ii), 18.1 (a), 18.4 (g), 18.4 (h) ii, 19.4, 20.4, (in the open market means distributor/ Dealer permissible). | |
| 19. | 4 (c) Tenderer shall be a manufacturer of the quoted product and having valid own manufacturing license in the indicate pharmacopeia (in technical specification at Annexure IA) and Certificate of Pharmaceutical Product (COPP) as recommended by WHO in any of the pharmacopeia IP/BP/USP/IHS (In-House | 4 (c), (e), (h) & Pg No. 7 | In case, bidder is Authorized Agent of the manufacturer in India then the past supply criteria of the self/ principal (manufacturer) could be considered. | Clarified as: Kindly follow the tender terms & conditions. |

| | standard). The manufacturing license & COPP should be valid on the date of tender opening packet 1. In case of failure to submit the same, the bid shall not be considered any further. 4 (e) (i) Average Annual turnover for Tenderers in the last three years i.e. 2020-21, 2021-22 and 2022-23 OR 2021-22, 2022-23 and 2023-24 shall not be less than the following: Rs 108,46,15,333/- (ii) The turnover benchmark given in (e) above will not apply to Micro and Small Enterprises (MSE). Note: MSE Traders will not get the benefits of MSE Firm 4 (h) Tenderer should have supplied 20% of the quoted quantity of same or similar items during the last two financial years. Bidder should submit Purchase order copies and certificate duly issued by statutory auditor/Practicing Chartered Accountant of the company on his letter head by certifying the quantities manufactured and marketed in trade, export, open market, sold to government institutions, private bodies etc. and the marketed quantities are not less than at least 20% of the quoted/similar items. Similar Items here relate to the following: - Similar item means quoted/any ARV Drug | | | |
|-----|---|---|---|---|
| 20. | | 6.2 (c), (e), (f), | In case, bidder is Authorized Agent of the manufacturer | Clarified as: |
| | | (g), (h), (i), (j), (n), aa & Pg No. | criteria of the self/ principal (manufacturer) could be | Kindly follow the tender terms & conditions. |
| | | 11-13 | considered. | |
| 21. | | | | Clarified as: |

| | | | Please clarify if any litigation or sub-Judice matter happened with defaulting suppliers, as there is huge financial involvement. | Kindly follow the tender terms & conditions. |
|-----|--|------------------|---|--|
| 22. | Tender Title Name:- Online risk purchase tender for procurement of Tenofovir 300mg+ Lamivudine 300mg+ Dolutegravir 50mg (TLD) for NACO. | Pg No. 1 | Tender Title Name amended as: - Tender for procurement of Tenofovir 300mg+ Lamivudine 300mg+ Dolutegravir 50mg (TLD) for NACO. Reasons: - Online risk purchase indicates to provoke to quote higher | Clarified as: Kindly follow the tender terms & conditions. |
| | | | prices | |
| 23. | This tender is for procurement of Tenofovir 300mg+ Lamivudine 300mg+ Dolutegravir 50mg (TLD) for NACO at the risk & cost of the defaulter supplier against CMSS Purchase Order No. CMSS/PROC/2023- 24/NACO/021/059 & CMSS/PROC/2023- 24/NACO/021/060 dated 03/10/2023 awarded against tender no. CMSS/PROC/2023- 24/NACO/021 opened on 25/07/2023. | Pg No. 5 | Kindly remove the such point. Reasons: - Such conditions to provoke to quote higher rates because quoted rates will be recovered by defaulting suppliers | Clarified as: Kindly follow the tender terms & conditions. |
| 24. | Tender should not be | 4 (f) & | Amended as Tender Clause | Clarified as: |
| | blacklisted/ banned/ debarred (as whole) or for the tendered goods by CMSS, MoHFW and Department of Expenditure on the date of tender opening. Aforesaid debarred/banned/blacklisted bidder are not eligible to bid in the tender. | Pg No. 7 | 4.f- Eligibility Criteria In addition to the existing tender clause, Those tenderer have also eligible to participate which was filled the court cases against procurement agency before tender publishing date or Hon'ble court grant stay order against blacklisting orders | Kindly follow the tender terms & conditions. |
| 25. | Defaulting vendors whose EMD/SD has been forfeited by CMSS in last two years shall be summarily rejected. | 4 (i) & Pg No. 8 | Such condition may pl deleted. Reasons: - SD forfeiture is not determine the quality of the product. Those tenderer have also eligible to participate which was filled the court cases against procurement agency before tender publishing date or Hon'ble court grant stay order. | Clarified as: Kindly follow the tender terms & conditions. |

| 26. | Duly notarized general power of Attorney (on non-judicial stamp paper of worth Rs. 50/-) in favour of authorized signatory in case of partnership firm (to be signed by all partners) / proprietorship firm or board resolution in case of a company to sign the bid and bind the bidder. The signature of authorized signatory should be duly attested. In case of proprietorship on its letter head of firm declares himself as proprietor with specimen signature. | 6.2 (d) & Pg No. 11 | Duly notarized general power of Attorney (on non-judicial stamp paper of worth Rs. 50/- or More) in favour of authorized signatory in case of partnership firm (to be signed by all partners) / proprietorship firm or board resolution in case of a company to sign the bid and bind the bidder. The signature of authorized signatory should be duly attested. In case of proprietorship on its letter head of firm declares himself as proprietor with specimen signature. | Clarified as: Accepted. |
|-------------------|---|-------------------------------------|---|---|
| 27. | Annexure-VIII NOTARISED NDERTAKING BY MSE COMPANIES (In 20- Rupees stamp paper) | Annexu re-VIII & Pg No. 57 | Annexure-VIII NOTARISED UNDERTAKING BY MSE COMPANIES (In 20- Rupees or more rupees stamp paper) | Clarified as: Accepted. |
| 28. | | Annexu re-I & Pg No. 35 | Refer to this point, please confirm is there is only 1 product TLD to be quoted or Dolutegravir 50mg is also to be quoted, if yes, please confirm the quantity & supply details of the same. | Clarified as: Kindly follow the tender terms & conditions. |
| <i>c</i> - | | | | |
| 29. | Technical Specification | Annexu re-I & Pg No. 35 | Request to allow Skip Test of Microbial test & remove Nitrosamine test As per WHO guideline Microbial test is done on first five Commercial batches & then after on first and every 10th batch of the year whichever is earlier. (Enclosed herewith the WHO Guideline copy for your reference). | Clarified as: Kindly follow the tender terms & conditions. |
| 29. 30. 31. | Technical Specification | re-I & Pg | Microbial test & remove Nitrosamine test As per WHO guideline Microbial test is done on first five Commercial batches & then after on first and every 10th batch of the year whichever is earlier. (Enclosed herewith the WHO | Kindly follow the tender terms |

| | and to while uploading the documents we have to compress the file size until the documents get upload in Eaushadhi portal. Also it is necessary to follow UNSDG rule (United Nations Sustainable Development Goal) to save natural resources | |
|--|--|--|
|--|--|--|

Note: - Above changes will be part of the tender document.

-sd/ GM (Procurement)